The Board has initiated this review aiming to optimize shareholder value following its recent decision to discontinue the PARADIGME study for Nordic Nanovector’s lead asset Betalutin and implement a restructuring of the company.
The company’s Board of Directors has appointed Carnegie Investment Bank to explore strategic options available to the company.
“The decision to discontinue the PARADIGME study was extremely disappointing. As a result, we are now focused on achieving an outcome for the company that creates maximum value for shareholders. We believe this should include exploring all strategic options and, as a leading financial advisor in the Nordic region, Carnegie is strongly positioned to help us achieve the best possible outcome for our shareholders and other stakeholders,” says Chairman, Jan H. Egberts.
No assurances can be given as to the outcome or timing of the review process, the company states.
Photo: Nordic Nanovector